title: [Liposomal cytarabine for the treatment of leptomeningeal dissemination of central nervous system tumours in children and adolescents].
abstract: Leptomeningeal dissemination in paediatric central nervous system (CNS) tumours is associated with a poor outcome, and new therapeutic strategies are desperately needed. One of the main difficulties in the treatment of CNS tumours is blood brain barrier penetration. Intrathecal therapy has shown to be effective in several paediatric tumours. The aim of this article is to review the data available on the use of liposomal cytarabine for paediatric patients with leptomeningeal dissemination of CNS tumours, including the pharmacology, administration route, safety and efficacy data.
authors.affiliation: Servicio de Onco-Hematología Pediátrica, Hospital Infantil Universitario Niño Jesús, Madrid, España; Instituto de Investigación La Princesa, Madrid, España. Electronic address: lmorenom@ext.cnio.es.
authors.forename: Lucas
authors.initials: L
authors.lastname: Moreno
authors.affiliation: Servicio de Oncología Pediátrica, Hospital de Cruces, Bilbao, Vizcaya, España.
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: García Ariza
authors.affiliation: Servicio de Hemato-Oncología, Hospital Sant Joan de Déu, Barcelona, España.
authors.forename: Ofelia
authors.initials: O
authors.lastname: Cruz
authors.affiliation: Servicio de Oncología Pediátrica, Hospital Miguel Servet, Zaragoza, España.
authors.forename: Carlota
authors.initials: C
authors.lastname: Calvo
authors.affiliation: Servicio de Oncología Pediátrica, Hospital Virgen de la Arrixaca, Murcia, España.
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Fuster
authors.affiliation: Servicio de Oncología Pediátrica, Hospital Son Espases, Palma de Mallorca, Islas Baleares, España.
authors.forename: Jose Antonio
authors.initials: JA
authors.lastname: Salinas
authors.affiliation: Servicio de Oncología Pediátrica, Hospital General de Alicante, Alicante, España.
authors.forename: Cristina
authors.initials: C
authors.lastname: Moscardo
authors.affiliation: Servicio de Oncología Pediátrica, Hospital Universitario de Burgos, Burgos, España.
authors.forename: Raquel
authors.initials: R
authors.lastname: Portugal
authors.affiliation: Servicio de Oncología Pediátrica, Hospital Universitario de Burgos, Burgos, España.
authors.forename: Jose Manuel
authors.initials: JM
authors.lastname: Merino
authors.affiliation: Servicio de Onco-Hematología Pediátrica, Hospital Infantil Universitario Niño Jesús, Madrid, España; Instituto de Investigación La Princesa, Madrid, España.
authors.forename: Luis
authors.initials: L
authors.lastname: Madero
mesh_terms: D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage*; D006801:Humans; D008081:Liposomes; D008577:Meningeal Neoplasms / Q000188:drug therapy*; D009361:Neoplasm Invasiveness
chemical_list: D000964:Antimetabolites, Antineoplastic; D008081:Liposomes; D003561:Cytarabine
keywords: Central nervous system tumours; Citarabina liposomal; Diseminación leptomeníngea; Ependimoma; Ependymoma; Intratecal; Intrathecal; Leptomeningeal dissemination; Liposomal cytarabine; Medulloblastoma; Meduloblastoma; Tumores del sistema nervioso central